U.S. Food and Drug Administration Benefit‐Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission

On December 22, 2017, the U.S. Food and Drug Administration (FDA) updated the product label for nilotinib to include information for providers on how to discontinue this drug in certain patients. With the updated dosing recommendations, select patients with chronic phase myeloid leukemia (CML) takin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Pulte, E. Dianne, Wroblewski, Tanya, Bloomquist, Erik, Tang, Shenghui, Farrell, Ann, Deisseroth, Albert, McKee, Amy E., Pazdur, Richard
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2019
Schlagworte:
Regulatory Issues: FDA
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6516133/
https://ncbi.nlm.nih.gov/pubmed/31019020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0759
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge